KAPANYSE

Kairos Pharma, LTD.

Healthcare·Oncology·Phase 2·Los Angeles, CA, United States
OncologyImmunology

Kairos Pharma, LTD. (KAPA): 7 pipeline candidates · ~11 mo cash runway. Updated within the last hour.

7.3/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway3.1

11.3 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Kairos Pharma, LTD.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$9.4M

Cash

$3.7M

Quarterly Burn

$1.0M

Runway

11.3 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~May 2027
Today~12 mo out
Catalyst within runway

Pipeline (7 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

8

Total value held

$402K

HolderSharesValue
vanguard capital management llc463,756$259K
geode capital management, llc111,290$62K
vanguard fiduciary trust co63,884$36K
two sigma investments, lp39,543$22K
state street corp24,100$13K
two sigma securities, llc16,247$9K
hrt financial lp21,575$12
citigroup inc10$6
·CEO: Dr. John S. Yu M.D., Ph.D.

Frequently asked questions

How many drug candidates are in Kairos Pharma, LTD.'s pipeline?

Kairos Pharma, LTD. (KAPA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Kairos Pharma, LTD.'s lead drug candidate?

Kairos Pharma, LTD.'s most advanced tracked candidate is env 105 (Phase 2) for prostate cancer and non-small cell lung cancer.

What is Kairos Pharma, LTD.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Kairos Pharma, LTD. has approximately 11.3 months of cash runway.

What is Kairos Pharma, LTD.'s market capitalization?

Kairos Pharma, LTD.'s market capitalization is approximately $9.4M.

Who is the CEO of Kairos Pharma, LTD.?

Dr. John S. Yu M.D., Ph.D. is the chief executive officer of Kairos Pharma, LTD. (KAPA).

Get the full picture on Kairos Pharma, LTD.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.